Suppr超能文献

首个右向开放阅读框激酶2(RIOK2)分子胶降解剂实例的发现。

Discovery of the first examples of right open reading frame kinase 2 (RIOK2) molecular glue degraders.

作者信息

Ma Haowen, Liu Cong, Li Zihao, Yu Qiuchun, Xiong Huilan, Huang Chaomin, Tan Li, Zhan Min, Zhang Zhang, Cai Qian

机构信息

College of Chemistry and Materials Science, Zhejiang Normal University, No. 688 Yingbin Road, Jinhua, Zhejiang Province, 321004, China; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510530, China.

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510530, China.

出版信息

Eur J Med Chem. 2025 Feb 5;283:117166. doi: 10.1016/j.ejmech.2024.117166. Epub 2024 Dec 15.

Abstract

Right open reading frame kinase 2 (RIOK2) is an atypical serine threonine kinase which plays an important role in regulating ribosome synthesis and cell cycle progression. RIOK2 has been implicated in multiple human cancers and is a potential target for cancer treatment. We previously reported the discovery of CQ211 as a potent and selective RIOK2 inhibitor. Herein we present the design, synthesis, and evaluation of the first RIOK2 molecular glue degrader CQ627 based on the structure of CQ211. CQ627 can effectively induce the degradation of RIOK2 with a DC value of 410 nM in MOLT4 leukemia cell line via UPS by recruiting E3 ubiquitin ligase RNF126, while the corresponding small molecular inhibitor CQ211 barely induces any degradation at higher concentration of 10 μM. Moreover, CQ627 dose-dependently induces apoptosis and blocks cell cycles in G2/M phase in MOLT4 leukemia cells. Importantly, it also displays stronger antiproliferative activities in a variety of cancer cell lines than RIOK2 inhibitor CQ211 and demonstrates promising in vivo efficacy in a mouse MOLT4 xenograft model.

摘要

右开放阅读框激酶2(RIOK2)是一种非典型丝氨酸苏氨酸激酶,在调节核糖体合成和细胞周期进程中发挥重要作用。RIOK2与多种人类癌症有关,是癌症治疗的潜在靶点。我们之前报道了CQ211作为一种有效且选择性的RIOK2抑制剂的发现。在此,我们基于CQ211的结构介绍了首个RIOK2分子胶降解剂CQ627的设计、合成及评估。CQ627可通过招募E3泛素连接酶RNF126,在MOLT4白血病细胞系中通过泛素-蛋白酶体系统(UPS)以410 nM的DC值有效诱导RIOK2的降解,而相应的小分子抑制剂CQ211在10 μM的较高浓度下几乎不诱导任何降解。此外,CQ627在MOLT4白血病细胞中剂量依赖性地诱导凋亡并阻断细胞周期于G2/M期。重要的是,它在多种癌细胞系中也显示出比RIOK2抑制剂CQ211更强的抗增殖活性,并在小鼠MOLT4异种移植模型中展现出有前景的体内疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验